Purified anti-Tau 15-25 Antibody anti-Tau 15-25 - TAU-13,BioLegend,835204

Host

Mouse

Reactivity

Human

Application

WB -Quality tested

Platform ID

BAB781026980

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NamePurified anti-Tau 15-25 Antibody anti-Tau 15-25 - TAU-13
Cat. No.835204
HostMouse
RRIDAB_2728542 (BioLegend Cat. No. 835203)AB_2728543 (BioLegend Cat. No. 835204)
IsotypeMouse IgG1, κ
ReactivityHuman
ApplicationWB -Quality tested
ClonalityMonoclonal
Clone NumberTAU-13
Concentration0.5 mg/ml
TargetTau 15-25
ImmunogenPreliminary assignment of its epitope indicates that it maps to amino acid residues 15-25 on the longest isoform of human Tau.
PurityThe antibody was purified by affinity chromatography.
FormulationPhosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C.
Regulatory StatusResearch Use Only

Scientific Background

Tau protein promotes microtubule assembly and stability. Tau is abundant in neurons of the central nervous system, and is expressed at low levels in astrocytes and oligodendrocytes. Abnormal hyper-phosphorylation, aggregation, and toxic gain of function of tau is associated with several neurological disorders, including Alzheimer’s disease (AD). The major building block of neurofibrillary lesions in AD brains consists of paired helical filaments (PHFs) of abnormally hyperphosphorylated tau. Six isoforms of tau are generated by alternative splicing of the MAPT gene. These isoforms are distinguished by the number of tubulin binding domains, 3 (3R) or 4 (4R), in the C-terminal of the protein and by one (1N), two (2N), or no (0N) inserts in the N-terminal domain.  Tau isoforms are differentially expressed during development.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.